Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

In advanced lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have an excellent and long-lasting therapeutic response; however, virtually all patients eventually develop drug resistance and expe...

Full description

Bibliographic Details
Main Authors:	Shubin Chen, Qitao Yu, Wei Jiang, Yukun Lu, Yun Zhao, Huilin Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Medicine
Subjects:	advanced lung adenocarcinoma EGFR exon 19 deletion immunotherapy EGFR-TKI rechallenge
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1168220/full

Similar Items

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib
by: Yinyin Xue, et al.
Published: (2025-03-01)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
by: Taishu Wang, et al.
Published: (2018-07-01)

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance
by: Ao Juan, et al.
Published: (2024-09-01)

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
by: Hee Sun Park, et al.
Published: (2021-02-01)

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
by: Lin HUANG, et al.
Published: (2022-11-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment
by: Stephen Johan Prasetyo, et al.
Published: (2023-05-01)

The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia
by: Elisna Syahruddin, et al.
Published: (2025-01-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
by: Haoran Qi, et al.
Published: (2024-03-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024-06-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
by: Pascal Wang, et al.
Published: (2022-07-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
by: Kazumi Nishino, MD, PhD, et al.
Published: (2024-02-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status
by: Rui Yan, et al.
Published: (2023-05-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01)

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
by: Nunzio Digiacomo, et al.
Published: (2023-03-01)

A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
by: Kai Sun, et al.
Published: (2024-12-01)

Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance
by: Jinke Zhuge, et al.
Published: (2022-11-01)

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
by: Dantong Sun, et al.
Published: (2023-03-01)

Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
by: Zhou Y, et al.
Published: (2024-09-01)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
by: Jun-Feng Liu, et al.
Published: (2023-03-01)

Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
by: Chao-Wen Lu, et al.
Published: (2023-01-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
by: Kiran Munawar, et al.
Published: (2022-11-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
by: Christine Parseghian, et al.
Published: (2023-09-01)